Physician profile
John P Williams
NPI 1144220369
$6,336.40
in general payments reported to CMS, 2019-2025
27 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $622 · 2021: $1,464 · 2022: $1,410 · 2023: $980 · 2024: $546 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,900.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,902.51 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $596.27 | 2021-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $518.00 | 2023-2025 | |
| Lilly USA, LLC | $502.69 | 2019-2025 | Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $342.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.36 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $260.13 | 2020-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $253.56 | 2022-2025 | Caplyta |
| Allergan, INC. | $232.11 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $224.11 | 2019-2022 | |
| Pfizer INC. | $200.35 | 2019-2024 | |
| Amgen INC. | $152.90 | 2019-2024 | Otezla, Enbrel |
| Nestle Healthcare Nutrition INC. | $127.11 | 2021-2023 | |
| Alkermes, INC. | $123.29 | 2023-2024 | Aristada, Lybalvi |
| Biohaven Pharmaceuticals, INC. | $100.85 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $95.86 | 2021 | |
| Biodelivery Sciences International, INC. | $82.10 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $66.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.79 | 2019-2020 | |
| Saluda Medical Americas, INC. | $49.45 | 2023 | Evoke Scs |
| Teva Pharmaceuticals USA, INC. | $49.24 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.20 | 2022 | |
| Glaxosmithkline, LLC. | $26.25 | 2020 | |
| Abbott Laboratories | $18.15 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.51 | 2025 | Abilify Maintena |
| Sanofi-Aventis U.S. LLC | $13.37 | 2021 | |
| Aimmune Therapeutics, INC. | $13.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.